AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33513929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 73
Study 32719307 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-tacrolimus
Number of subjects: 496
Study 32719307 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tacrolimus
Number of subjects: 496
Study 35996282 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin plus an optimized background regimen
Number of subjects: 255
Study 35996282 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 255
Study 36079750 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Amino Acid mix (TRG)
Number of subjects: 22
Study 36079750 — intervention group
Group type: COMPARATOR
Intervention: Placebo mix (PLG)
Number of subjects: 22
Study 33658545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest BPV group
Number of subjects: 746
Study 33658545 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest BPV group
Number of subjects: 746
Study 33658545 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BPV
Number of subjects: 746
Study 33658545 — intervention group
Group type: COMPARATOR
Intervention: Mean systolic BP
Number of subjects: 746
Study 32398040 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT and 6 months of ADT
Number of subjects: 0
Study 32398040 — intervention group
Group type: COMPARATOR
Intervention: WPRT added to MDT and 6 months of ADT
Number of subjects: 0
Study 33297668 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 33297668 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with ASCT
Number of subjects: 0
Study 33297668 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy without ASCT
Number of subjects: 0
Study 32914728 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-functioning adrenal incidentalomas (NFAI) group
Number of subjects: 55
Study 32914728 — intervention group
Group type: EXPERIMENTAL
Intervention: NFAI group with CAC score <100
Number of subjects: 55
Study 32914728 — intervention group
Group type: EXPERIMENTAL
Intervention: NFAI group with CAC score ?100
Number of subjects: 55
Study 32914728 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 32663102 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 110 µg/glycopyrronium 50 µg once daily (OD)
Number of subjects: 50
Study 32663102 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 50 µg OD
Number of subjects: 50
Study 32663102 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Number of subjects: 50
Study 36460536 — intervention group
Group type: EXPERIMENTAL
Intervention: ERUCoV-VAC 3 μg
Number of subjects: 294
Study 36460536 — intervention group
Group type: EXPERIMENTAL
Intervention: ERUCoV-VAC 6 μg
Number of subjects: 294
Study 36460536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 33627077 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS therapy during the first stage of labor
Number of subjects: 326
Study 33627077 — intervention group
Group type: COMPARATOR
Intervention: Routine obstetric care (control group)
Number of subjects: 326
Study 32533013 — intervention group
Group type: EXPERIMENTAL
Intervention: Local tissue electrical parameters (TEPs) measured during the first week of radiation therapy.
Number of subjects: 135
Study 32533013 — intervention group
Group type: EXPERIMENTAL
Intervention: Local impedance module and resistance (TEPs)
Number of subjects: 135
Study 32533013 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT)
Number of subjects: 135
Study 35595661 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-214 vaccine (15/15, 15/50, 50/50, or 50/150 μg of GI.1/GII.4c genotype VLPs with 0.5 mg Al(OH)3)
Number of subjects: 240
Study 33476659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol (200 mg oral mifepristone followed by 800 mcg vaginal misoprostol)
Number of subjects: 139
Study 34939823 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to mother's scent (n = 52)
Number of subjects: 104
Study 34939823 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 52)
Number of subjects: 104
Study 33870612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging intervention targeting dietary behaviours
Number of subjects: 25
Study 32234296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase cleaning of bedroom FTPs
Number of subjects: 300
Study 32234296 — intervention group
Group type: COMPARATOR
Intervention: Control phase cleaning of bathroom FTPs
Number of subjects: 300
Study 32234296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase cleaning of bathroom FTPs
Number of subjects: 300
Study 33687525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1422
Study 33687525 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (JAK inhibitor)
Number of subjects: 1422
Study 33554776 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsible Behavior with Younger Children (RBYC) program
Number of subjects: 0
Study 32568092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received short instant messages through an app over 4 months.
Number of subjects: 640
Study 32568092 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard family planning information and control messages through the same app.
Number of subjects: 640
Study 36455430 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone coaching
Number of subjects: 230
Study 36455430 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message coaching
Number of subjects: 230
Study 36455430 — intervention group
Group type: COMPARATOR
Intervention: No support control group
Number of subjects: 230
Study 33578362 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket costs for hospitalization
Number of subjects: 800
Study 33578362 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophic health expenditures
Number of subjects: 800
Study 33578362 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of length of stay, elimination of the need for next of kin, provision of healthcare services out of hospitals
Number of subjects: 800
Study 35596620 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based adherence intervention
Number of subjects: 200
Study 35596620 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence (≥95%)
Number of subjects: 200
Study 35596620 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES), child race, family functioning, parent distress
Number of subjects: 200
Study 35725922 — intervention group
Group type: EXPERIMENTAL
Intervention: Licogliflozin 150 mg
Number of subjects: 107
Study 35725922 — intervention group
Group type: EXPERIMENTAL
Intervention: Licogliflozin 30 mg
Number of subjects: 107
Study 35725922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 33463868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Screening (NRS 2002) by nursing students
Number of subjects: 508
Study 35943499 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigational surgical template in vestibuloplasty protocol
Number of subjects: 48
Study 35943499 — intervention group
Group type: COMPARATOR
Intervention: Classical technology in vestibuloplasty
Number of subjects: 48
Study 34779225 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration (TA) during primary PCI
Number of subjects: 9147
Study 34779225 — intervention group
Group type: COMPARATOR
Intervention: Non-thrombus aspiration (non-TA) during primary PCI
Number of subjects: 9147
Study 32663919 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally applied topical fluoride (DHSU‐PATF)
Number of subjects: 1404
Study 36106611 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteus Discover adherence system with TDF/FTC
Number of subjects: 100
Study 36106611 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care TDF/FTC
Number of subjects: 100
Study 36106611 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteus Discover adherence system
Number of subjects: 100
Study 33980288 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Acupuncture (BA)
Number of subjects: 32
Study 33980288 — intervention group
Group type: COMPARATOR
Intervention: Needle Duration (ND)
Number of subjects: 32
Study 33980288 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 32
Study 32590371 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric anodic‐first (AA) stimulation
Number of subjects: 3
Study 32590371 — intervention group
Group type: COMPARATOR
Intervention: Standard symmetric cathodic‐first (SC) pulse
Number of subjects: 3
Study 32590371 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric stimuli with large duration ratios (≥20)
Number of subjects: 3
Study 32590371 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric cathodic‐first (AC) stimuli
Number of subjects: 3
Study 32590371 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric anodic‐first (AA) stimulation with small duration ratios (≤5) and long IPGs (≥2 ms)
Number of subjects: 3
Study 32590371 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric anodic‐first (SA) stimulation
Number of subjects: 3
Study 35759319 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based educational intervention and WhatsApp follow-up; delivered in two stages: face-to-face and WhatsApp follow-up.
Number of subjects: 401
Study 35759319 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 401
Study 33157498 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-oxide impregnated sanitary towel (study group)
Number of subjects: 450
Study 33157498 — intervention group
Group type: COMPARATOR
Intervention: Non-copper sanitary towel (control group)
Number of subjects: 450
Study 32332638 — intervention group
Group type: EXPERIMENTAL
Intervention: Jade moxibustion
Number of subjects: 148
Study 32332638 — intervention group
Group type: COMPARATOR
Intervention: Traditional moxibustion
Number of subjects: 148
Study 33593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including nutrition optimization, parenting program with cognitive-behavioral therapy, lifestyle behavior change, and reduction of environmental pollution.
Number of subjects: 6000
Study 33593789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 6000
Study 33039655 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit from Home (FFH) campaign
Number of subjects: 8942
Study 33039655 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 pandemic
Number of subjects: 8942
Study 35262602 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 150
Study 35262602 — intervention group
Group type: COMPARATOR
Intervention: Usual service care
Number of subjects: 150
Study 33068667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 126
Study 33068667 — intervention group
Group type: COMPARATOR
Intervention: Listening to a news article (Control)
Number of subjects: 126
Study 32065939 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE (integrated treatment using prolonged exposure)
Number of subjects: 119
Study 32065939 — intervention group
Group type: COMPARATOR
Intervention: Seeking Safety (integrated therapy using cognitive behavioral, interpersonal techniques and case management)
Number of subjects: 119
Study 35074903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg)
Number of subjects: 19
Study 35074903 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg) + Nivolumab (1 mg/kg)
Number of subjects: 19
Study 33663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/Low Carbohydrate (MED/LC) diet
Number of subjects: 120
Study 33663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Fat (LF) diet
Number of subjects: 120
Study 33663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weight losers (> 5% weight loss)
Number of subjects: 120
Study 33663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss failures
Number of subjects: 120
Study 33663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with healthy liver fat content (< 5% IHF)
Number of subjects: 120
Study 33663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with fatty liver
Number of subjects: 120
Study 33663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall weight-loss lifestyle intervention
Number of subjects: 120
Study 616191276 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (150 mg twice daily)
Number of subjects: 300
Study 616191276 — intervention group
Group type: COMPARATOR
Intervention: Varenicline (1 gm twice daily)
Number of subjects: 300
Study 616191276 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline + Bupropion (1 gm twice daily + 150 mg twice daily)
Number of subjects: 300
Study 36262221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted person-centered prescription (PCP) model
Number of subjects: 114
Study 36262221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 32895890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training delivered using CoRe software (CCT)
Number of subjects: 53
Study 32895890 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper-and-pencil cognitive training (PCT)
Number of subjects: 53
Study 32895890 — intervention group
Group type: COMPARATOR
Intervention: Unstructured activity intervention (CG)
Number of subjects: 53
Study 35063621 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 litres per minute of air in front of mouth/nose into the air pocket
Number of subjects: 20
Study 35063621 — intervention group
Group type: COMPARATOR
Intervention: No air
Number of subjects: 20
Study 34002406 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional-guided bibliotherapy sessions (8 weekly sessions)
Number of subjects: 60
Study 35061868 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) for 9 weeks
Number of subjects: 144
Study 35061868 — intervention group
Group type: COMPARATOR
Intervention: Online discussion forum (ODF)
Number of subjects: 144
Study 34894454 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA undetectable at week 8
Number of subjects: 86
Study 34894454 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA undetectable at week 8 in patients with stable disease (SD)
Number of subjects: 86
Study 34894454 — intervention group
Group type: COMPARATOR
Intervention: ctDNA undetectable vs detectable in patients with PR at week 8
Number of subjects: 86
Study 34894454 — intervention group
Group type: COMPARATOR
Intervention: ctDNA undetectable vs detectable in patients with SD at week 8
Number of subjects: 86
Study 33290772 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 μg (VP250)
Number of subjects: 130
Study 33290772 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 100 μg (VP100)
Number of subjects: 130
Study 33290772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB) followed by Viaskin Peanut 250 μg (PLB-VP250)
Number of subjects: 130
Study 615918678 — intervention group
Group type: EXPERIMENTAL
Intervention: 532 nm laser exposure during driving tests
Number of subjects: 10
Study 615918678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun visor folded down during laser exposure
Number of subjects: 10
Study 615918678 — intervention group
Group type: COMPARATOR
Intervention: Driving without laser exposure
Number of subjects: 10
Study 35263172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative detection of pathogens in subcutaneous tissue
Number of subjects: 393
Study 35263172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative detection of Enterococcus faecium
Number of subjects: 393
Study 35263172 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive subcutaneous swab
Number of subjects: 393
Study 35263172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative anemia
Number of subjects: 393
Study 35263172 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 393
Study 33496955 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed extra-mucosal running suture (stapler-less)
Number of subjects: 40
Study 33496955 — intervention group
Group type: COMPARATOR
Intervention: Standard stapler line
Number of subjects: 40
Study 33496955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (stapler-less and standard stapler)
Number of subjects: 40
Study 32100683 — intervention group
Group type: EXPERIMENTAL
Intervention: VAPE® portable set (spatial repellent device)
Number of subjects: 21
Study 35483627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxie
Number of subjects: 240
Study 35483627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 33879733 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP group (basic treatment combined with rhBNP)
Number of subjects: 300
Study 33879733 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential treatment group (basic treatment for heart failure combined with rhBNP followed by sacubitril/valsartan)
Number of subjects: 300
Study 33879733 — intervention group
Group type: COMPARATOR
Intervention: standard treatment group (treated with an angiotensin‐converting enzyme inhibitor, β receptor blocker, and corticosteroid antagonist)
Number of subjects: 300
Study 34253665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 60
Study 34253665 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 60
Study 34970718 — intervention group
Group type: COMPARATOR
Intervention: rTMS‐COG (repetitive transcranial magnetic stimulation combined with cognitive training)
Number of subjects: 72
Study 34970718 — intervention group
Group type: COMPARATOR
Intervention: rTMS‐COG
Number of subjects: 72
Study 34970718 — intervention group
Group type: COMPARATOR
Intervention: EEG parameters
Number of subjects: 72
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: CT model for lung cancer incidence
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model for lung cancer incidence
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: CT model for lung cancer incidence (validation cohort)
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model for lung cancer incidence (validation cohort)
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model for CVD mortality
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey model for CVD mortality
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: CT model for CVD mortality
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model for COPD mortality
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey model for COPD mortality
Number of subjects: 15000
Study 33574075 — intervention group
Group type: EXPERIMENTAL
Intervention: CT model for COPD mortality
Number of subjects: 15000
Study 32073202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Art Therapy (MBAT)
Number of subjects: 77
Study 32073202 — intervention group
Group type: COMPARATOR
Intervention: Neutral Clay Task (NCT)
Number of subjects: 77
Study 35382758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 30
Study 35382758 — intervention group
Group type: COMPARATOR
Intervention: General Health Education (GHE)
Number of subjects: 30
Study 34057373 — intervention group
Group type: EXPERIMENTAL
Intervention: I-PLAN intervention (information about consequences of hearing aid use/nonuse, reminder prompt, action plan)
Number of subjects: 160
Study 34057373 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 160
Study 34057373 — intervention group
Group type: EXPERIMENTAL
Intervention: I-PLAN intervention
Number of subjects: 160
Study 32145994 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 89
Study 32145994 — intervention group
Group type: COMPARATOR
Intervention: HD-IIV3
Number of subjects: 89
Study 32145994 — intervention group
Group type: COMPARATOR
Intervention: aIIV3
Number of subjects: 89
Study 34708311 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic extraoral photobiomodulation (PBM)
Number of subjects: 55
Study 34708311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 33351346 — intervention group
Group type: COMPARATOR
Intervention: NAD(P)-dependent dehydrogenases activity in newly diagnosed GD patients
Number of subjects: 151
Study 33351346 — intervention group
Group type: COMPARATOR
Intervention: NAD(P)-dependent dehydrogenases activity in GD relapse group
Number of subjects: 151
Study 33351346 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between fT3 level and MDG activity in newly diagnosed GD patients
Number of subjects: 151
Study 33351346 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between fT4 level and NAD(P)-ICDH activity in newly diagnosed GD patients
Number of subjects: 151
Study 33351346 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TSH concentration and LDH activity in GD relapse patients
Number of subjects: 151
Study 33351346 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TSH concentration and MDH activity in GD relapse patients
Number of subjects: 151
Study 33351346 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between fT4 concentration and NADGDH activity in GD relapse patients
Number of subjects: 151
Study 35768976 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (150 mg/day and 15 mg/kg every 3 weeks)
Number of subjects: 152
Study 35768976 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 152
Study 35768976 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 152
Study 34948846 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM-based MI model intervention (7 counseling sessions)
Number of subjects: 107